Genenta Science S.p.A. (GNTA) Stock Price, Financials & Summary

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.3x

Market Cap

$46.75M

MomentumView details →

1D Return

+2.00%

YTD Return

−35.56%

RSI (14)

30.7

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.3x

Market Cap

$46.75M

RSI (14)

30.7

MomentumView details →

1D Return

+2.00%

YTD Return

−35.56%

SummaryUpdated Dec 1, 2025

Genenta Science S.p.A. (NASDAQ:GNTA) is a clinical-stage biotechnology company founded in 2014 and headquartered in Milan, Italy. The company went public on December 15, 2021, and specializes in developing innovative hematopoietic stem cell gene therapies for treating solid tumors. Genenta focuses on addressing some of the most challenging cancers, particularly brain tumors like glioblastoma multiforme, through its proprietary gene therapy platform that modifies patients' own stem cells to fight cancer.

Ask drillr about Genenta Science S.p.A. →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−70.57%

ROA (TTM)

−48.33%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+25.45%

FCF YoY

−85.42%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+32.65%

EBITDA YoY

+22.09%

EarningsView details →

EPS (Actual)

−$0.24

EPS Surprise

46.37%

Beats (12Q)

1/12

Next Q EPS Est

—

Avg Surprise (4Q)

46.37%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.35x

Current Ratio

14.16x

Quick Ratio

14.16x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−15.41M

Op. CF (TTM)

−7.72M

Next earningsMar 3, 2027 →

Latest newsMore news →

No recent news for GNTA.

Similar companies

Edesa Biotech, Inc.EDSA Werewolf Therapeutics, Inc.HOWL Veru Inc.VERU Tevogen Bio Holdings Inc.TVGN Celularity Inc.CELU aTyr Pharma, Inc.ATYR Find similar companies →

Latest newsMore news →

No recent news for GNTA.